Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 555Carcinoma, Non-Small-Cell Lung 507Prostatic Neoplasms 330Neoplasms 268Multiple Myeloma 266Colorectal Neoplasms 264Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 216Lung Neoplasms 209Neoplasm Metastasis 203Carcinoma, Hepatocellular 195Triple Negative Breast Neoplasms 172Melanoma 172Pancreatic Neoplasms 170Ovarian Neoplasms 150Recurrence 148Lymphoma 143Glioblastoma 134Brain Neoplasms 133Sarcoma 128Leukemia, Lymphocytic, Chronic, B-Cell 127Carcinoma, Renal Cell 127Lymphoma, Large B-Cell, Diffuse 125Stomach Neoplasms 124Head and Neck Neoplasms 120Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 107Myelodysplastic Syndromes 105Urinary Bladder Neoplasms 100Small Cell Lung Carcinoma 98

Interventions

Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colitis × 1 year × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡